Genicity aims to overcome the problem of T cell exhaustion with an allogenic T cell platform that can boost the efficacy of approved bispecific T cell engagers, and mimic the cells that drive responses to marketed immunotherapies. The company hopes to raise venture financing by the end of 2024. 

CEO Rainer Henning told BioCentury that Genicity Ltd. was founded to improve the success rates of bispecific T cell engagers, which he said are limited by T cell exhaustion, particularly in solid tumors...